Lupin receives approval from USFDA for Bromfenac Ophthalmic
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Need to harmonize traditional and modern medicine to combat alarming health problems
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Jeet will be a trusted partner in cardiovascular care
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Subscribe To Our Newsletter & Stay Updated